Major Bleeding Risk Assessment in Patients with Cancer-Associated Venous Thromboembolism Treated with DOACs: Data from a Multicenter Cohort
In cancer-associated venous thromboembolism (CAT), extended anticoagulation should be considered when the risk-benefit profile is favorable. However, optimal predictors of major bleeding (MB) remain unclear.This multicenter observational study included CAT patients treated with direct oral anticoagu...
Uloženo v:
| Vydáno v: | Thrombosis and haemostasis |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
03.06.2025
|
| ISSN: | 2567-689X, 2567-689X |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In cancer-associated venous thromboembolism (CAT), extended anticoagulation should be considered when the risk-benefit profile is favorable. However, optimal predictors of major bleeding (MB) remain unclear.This multicenter observational study included CAT patients treated with direct oral anticoagulants (DOACs). Study objectives were: (i) assess the performance of nine bleeding risk scores (ATRIA, CAT-BLEED, CHAP, DOAC, HAS-BLED, Kuijer, ORBIT, RIETE, VTE-BLEED), (ii) identify predictors of MB (ISTH definition), and (iii) propose an improved bleeding risk model (Perform score).Overall, 823 patients were followed (mean 1.6 years). MB occurred in 44 cases (3.4% per patient-year). The predictive performance of bleeding risk scores was modest (c-statistics range 0.513-0.606). Risk factors included increasing age (HR 1.04, 95% CI 1.00-1.07), use of steroids (HR 2.69, 95% CI 1.34-5.40), antimetabolites (HR 2.51, 95% CI 1.28-4.93), and unresected gastrointestinal cancer (HR 7.30, 95% CI 1.70-31.30). Conversely, prior cancer surgery (HR 0.41, 95% CI 0.20-0.82) and anticancer hormones (HR 0.22, 95% CI 0.05-0.92) showed a possible protective effect toward MB risk. The Perform score provided a slight enhancement in risk prediction (c-statistics 0.678), but remained suboptimal.In this real-world cohort of CAT patients treated with DOACs, unresected gastrointestinal cancer and use of steroids or antimetabolites were associated with increased MB risk, while prior cancer surgery and anticancer hormones were linked to a lower risk. These factors, not considered in current bleeding risk scores, may refine bleeding prediction. Further studies should clarify their role in guiding anticoagulation decisions and improving personalized risk assessment.In cancer-associated venous thromboembolism (CAT), extended anticoagulation should be considered when the risk-benefit profile is favorable. However, optimal predictors of major bleeding (MB) remain unclear.This multicenter observational study included CAT patients treated with direct oral anticoagulants (DOACs). Study objectives were: (i) assess the performance of nine bleeding risk scores (ATRIA, CAT-BLEED, CHAP, DOAC, HAS-BLED, Kuijer, ORBIT, RIETE, VTE-BLEED), (ii) identify predictors of MB (ISTH definition), and (iii) propose an improved bleeding risk model (Perform score).Overall, 823 patients were followed (mean 1.6 years). MB occurred in 44 cases (3.4% per patient-year). The predictive performance of bleeding risk scores was modest (c-statistics range 0.513-0.606). Risk factors included increasing age (HR 1.04, 95% CI 1.00-1.07), use of steroids (HR 2.69, 95% CI 1.34-5.40), antimetabolites (HR 2.51, 95% CI 1.28-4.93), and unresected gastrointestinal cancer (HR 7.30, 95% CI 1.70-31.30). Conversely, prior cancer surgery (HR 0.41, 95% CI 0.20-0.82) and anticancer hormones (HR 0.22, 95% CI 0.05-0.92) showed a possible protective effect toward MB risk. The Perform score provided a slight enhancement in risk prediction (c-statistics 0.678), but remained suboptimal.In this real-world cohort of CAT patients treated with DOACs, unresected gastrointestinal cancer and use of steroids or antimetabolites were associated with increased MB risk, while prior cancer surgery and anticancer hormones were linked to a lower risk. These factors, not considered in current bleeding risk scores, may refine bleeding prediction. Further studies should clarify their role in guiding anticoagulation decisions and improving personalized risk assessment. |
|---|---|
| AbstractList | In cancer-associated venous thromboembolism (CAT), extended anticoagulation should be considered when the risk-benefit profile is favorable. However, optimal predictors of major bleeding (MB) remain unclear.This multicenter observational study included CAT patients treated with direct oral anticoagulants (DOACs). Study objectives were: (i) assess the performance of nine bleeding risk scores (ATRIA, CAT-BLEED, CHAP, DOAC, HAS-BLED, Kuijer, ORBIT, RIETE, VTE-BLEED), (ii) identify predictors of MB (ISTH definition), and (iii) propose an improved bleeding risk model (Perform score).Overall, 823 patients were followed (mean 1.6 years). MB occurred in 44 cases (3.4% per patient-year). The predictive performance of bleeding risk scores was modest (c-statistics range 0.513-0.606). Risk factors included increasing age (HR 1.04, 95% CI 1.00-1.07), use of steroids (HR 2.69, 95% CI 1.34-5.40), antimetabolites (HR 2.51, 95% CI 1.28-4.93), and unresected gastrointestinal cancer (HR 7.30, 95% CI 1.70-31.30). Conversely, prior cancer surgery (HR 0.41, 95% CI 0.20-0.82) and anticancer hormones (HR 0.22, 95% CI 0.05-0.92) showed a possible protective effect toward MB risk. The Perform score provided a slight enhancement in risk prediction (c-statistics 0.678), but remained suboptimal.In this real-world cohort of CAT patients treated with DOACs, unresected gastrointestinal cancer and use of steroids or antimetabolites were associated with increased MB risk, while prior cancer surgery and anticancer hormones were linked to a lower risk. These factors, not considered in current bleeding risk scores, may refine bleeding prediction. Further studies should clarify their role in guiding anticoagulation decisions and improving personalized risk assessment.In cancer-associated venous thromboembolism (CAT), extended anticoagulation should be considered when the risk-benefit profile is favorable. However, optimal predictors of major bleeding (MB) remain unclear.This multicenter observational study included CAT patients treated with direct oral anticoagulants (DOACs). Study objectives were: (i) assess the performance of nine bleeding risk scores (ATRIA, CAT-BLEED, CHAP, DOAC, HAS-BLED, Kuijer, ORBIT, RIETE, VTE-BLEED), (ii) identify predictors of MB (ISTH definition), and (iii) propose an improved bleeding risk model (Perform score).Overall, 823 patients were followed (mean 1.6 years). MB occurred in 44 cases (3.4% per patient-year). The predictive performance of bleeding risk scores was modest (c-statistics range 0.513-0.606). Risk factors included increasing age (HR 1.04, 95% CI 1.00-1.07), use of steroids (HR 2.69, 95% CI 1.34-5.40), antimetabolites (HR 2.51, 95% CI 1.28-4.93), and unresected gastrointestinal cancer (HR 7.30, 95% CI 1.70-31.30). Conversely, prior cancer surgery (HR 0.41, 95% CI 0.20-0.82) and anticancer hormones (HR 0.22, 95% CI 0.05-0.92) showed a possible protective effect toward MB risk. The Perform score provided a slight enhancement in risk prediction (c-statistics 0.678), but remained suboptimal.In this real-world cohort of CAT patients treated with DOACs, unresected gastrointestinal cancer and use of steroids or antimetabolites were associated with increased MB risk, while prior cancer surgery and anticancer hormones were linked to a lower risk. These factors, not considered in current bleeding risk scores, may refine bleeding prediction. Further studies should clarify their role in guiding anticoagulation decisions and improving personalized risk assessment. |
| Author | Simioni, Paolo Sacco, Clara Beccatini, Sofia Mazzetti, Matteo Podda, Gian Marco Mastandrea, Isabella Pola, Roberto Talerico, Rosa Campello, Elena Becattini, Cecilia Caprari, Rachele Lodigiani, Corrado Birocchi, Simone Porfidia, Angelo Vedovati, Maria Cristina |
| Author_xml | – sequence: 1 givenname: Maria Cristina surname: Vedovati fullname: Vedovati, Maria Cristina – sequence: 2 givenname: Rosa surname: Talerico fullname: Talerico, Rosa – sequence: 3 givenname: Clara surname: Sacco fullname: Sacco, Clara – sequence: 4 givenname: Matteo surname: Mazzetti fullname: Mazzetti, Matteo – sequence: 5 givenname: Elena surname: Campello fullname: Campello, Elena – sequence: 6 givenname: Simone surname: Birocchi fullname: Birocchi, Simone – sequence: 7 givenname: Sofia surname: Beccatini fullname: Beccatini, Sofia – sequence: 8 givenname: Angelo surname: Porfidia fullname: Porfidia, Angelo – sequence: 9 givenname: Rachele surname: Caprari fullname: Caprari, Rachele – sequence: 10 givenname: Corrado surname: Lodigiani fullname: Lodigiani, Corrado – sequence: 11 givenname: Paolo surname: Simioni fullname: Simioni, Paolo – sequence: 12 givenname: Gian Marco surname: Podda fullname: Podda, Gian Marco – sequence: 13 givenname: Isabella surname: Mastandrea fullname: Mastandrea, Isabella – sequence: 14 givenname: Cecilia surname: Becattini fullname: Becattini, Cecilia – sequence: 15 givenname: Roberto surname: Pola fullname: Pola, Roberto |
| BookMark | eNpNT0tOwzAUtFBZlMKKC7wlm4CT1HHCrqT8JKoiFCF21YvzTA2JDbYrDsGliQoLFqMZaT7SHLGJdZYYO035ecqFuMAkK7hIKp6KAzbNRCGToqxeJv_0lH2v8M15uOqJOmNf4cmEd1iEQCEMZCMYC48YzSgDfJm4hRqtIp-MEacMRurgmazbBWi23g2toxG9CQM0nvb2vrVcL-pwCUuMCHrMAcJq10ejxmHyULut8_GYHWrsA5388Yw1N9dNfZc8rG_v68VDonKex6SjNtWd5pJzLDVqxEoh7_JWcdmiGi3JkeRc6KwSqiyFzguUUvK0w1zybMbOfmc_vPvcUYibwQRFfY-WxiObPEuFkHyey-wHYjhnlA |
| CitedBy_id | crossref_primary_10_1007_s00063_025_01311_7 |
| ContentType | Journal Article |
| Copyright | Thieme. All rights reserved. |
| Copyright_xml | – notice: Thieme. All rights reserved. |
| DBID | 7X8 |
| DOI | 10.1055/a-2605-9015 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 2567-689X |
| GroupedDBID | 7X8 |
| ID | FETCH-LOGICAL-c303t-deb1fdf0700a8fafaa9ca0d3bc07bacfdf70ae745f295c885f36a77701da3702 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001502790700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2567-689X |
| IngestDate | Wed Jul 02 02:47:18 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c303t-deb1fdf0700a8fafaa9ca0d3bc07bacfdf70ae745f295c885f36a77701da3702 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PQID | 3215570437 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3215570437 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-06-03 |
| PublicationDateYYYYMMDD | 2025-06-03 |
| PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationTitle | Thrombosis and haemostasis |
| PublicationYear | 2025 |
| Score | 2.4799461 |
| Snippet | In cancer-associated venous thromboembolism (CAT), extended anticoagulation should be considered when the risk-benefit profile is favorable. However, optimal... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| Title | Major Bleeding Risk Assessment in Patients with Cancer-Associated Venous Thromboembolism Treated with DOACs: Data from a Multicenter Cohort |
| URI | https://www.proquest.com/docview/3215570437 |
| WOSCitedRecordID | wos001502790700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDI6AceDCQ4B4y0hcq2XL0rRcEAwmDoAQmqbdJrdJtMFooZ34E_xp7K6DAxckDj2lkdrY-ew49mchzozq-DBJ4sAx2y2dvwgHEVXQip1y5EAbWSWPD-7Mw0M0HMaPdcCtrNMqF5hYAbXNU46RNxXZJm2Yiefi7T3grlF8u1q30FgWDUWuDGu1GVZN6DTt_zCKh3VJntS6iQH77pyPoH8Bb2VNehv__Y5NsV77kXA5F_yWWHLZtvi8x-e8gKvp3CTB06R8gctv7k2YZPA451EtgQOw0GWZF8FCRs7CoOJshf64yF-T3NEznZSv0GffkoarWXSe7JbncI0zBC5PAYSqjpcTPV0B3XxMPv2O6Pdu-t3boO62EKRkxmaBJdT21hMESIw8esQ4RWlVkkqTYEpDRqIzHe3bsU6jSHsVojEkTIvKyPauWMnyzO0J8NK6FsbSoded0DrmAAxN0lIt23G-7fbF6WJpR6TMfEOBmaOfG_0s7sEf3jkUa23uxssxEXUkGp42rDsWq-nHbFIWJ5UufAEa_sK5 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Major+Bleeding+Risk+Assessment+in+Patients+with+Cancer-Associated+Venous+Thromboembolism+Treated+with+DOACs%3A+Data+from+a+Multicenter+Cohort&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Vedovati%2C+Maria+Cristina&rft.au=Talerico%2C+Rosa&rft.au=Sacco%2C+Clara&rft.au=Mazzetti%2C+Matteo&rft.date=2025-06-03&rft.issn=2567-689X&rft.eissn=2567-689X&rft_id=info:doi/10.1055%2Fa-2605-9015&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2567-689X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2567-689X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2567-689X&client=summon |